Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Link to presentation - M402, a Heparan Sulfate Mimetic and Novel Candidate for the Treatment of Pancreatic Cancer

Check out -
PHASE 1/2 STUDY DESIGN

http://www.momentapharma.com/ASCO_2012_poster_4056.pdf

CONCLUSIONS -

• M402 modulated tumor-stroma interactions involved in metastatic and desmoplastic pathways in two pancreatic cancer models.
• In the genetically engineered mouse model:
• M402 in combination with gemcitabine prolonged survival, decreased metastases and local invasion, and inhibited epithelial-tomesenchymal transition.
• In the orthotopic Capan-2 pancreatic cancer model:
• M402 monotherapy showed a dose-dependent reduction in primary
tumor weight, while M402 in combination with gemcitabine almost
completely inhibited primary and metastatic tumor growth, which may be related to M402’s effect on SHH signaling.
• These results provide a rationale for investigating the clinical use of M402.

A first-in-human study has been initiated that will evaluate the safety,pharmacokinetics, efficacy, and biomarker profiles of escalating M402 doses in combination with gemcitabine in patients with metastatic pancreatic cancer.

• M402 can inhibit angiogenesis, tumor progression and metastasis in animal models by modulating a variety of polysaccharide-based binding proteins, which may support the clinical investigation of M402 in a range of cancers.

http://www.momentapharma.com/ASCO_2012_poster_4056.pdf